Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xoma
Biotech
Painted into a corner, Mural agrees to Xoma buyout
The writing has been on the wall for Mural since April, when the cancer company’s IL-2 variant failed a phase 2 melanoma trial.
Darren Incorvaia
Aug 20, 2025 10:28am
Xoma shops for struggling biotechs, buying HilleVax and Lava
Aug 4, 2025 9:27am
Turnstone, once allied with AbbVie, accepts $8M Xoma buyout
Jun 27, 2025 9:00am
ObsEva sells off one of 2 remaining assets to stay afloat
Nov 22, 2022 7:35am
Agenus sells cut of Incyte, Merck milestone streams
Sep 21, 2018 9:45am
Novartis buys Xoma’s failed IL-1 drug at a knockdown price
Aug 28, 2017 9:33am
